Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Top Agenda Maker: Commissioner, Congress – Or The Courts?

This article was originally published in The Tan Sheet

Executive Summary

Agency chief counsel says continued priority-setting through lawsuits eventually may affect public health, while professor says FDA discretion not to act is at stake in some cases.

You may also be interested in...

Draft Guidance More Than Meets The Eye? Senators Seek Answers From FDA

Republicans on the Senate HELP Committee say they are concerned that FDA is using draft guidance documents to set substantive policy, putting companies in a difficult position.

FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?

Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.

Lawsuit Seeking FDA Triclosan Action Stays Alive On Appeal

A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts